<DOC>
	<DOC>NCT00661284</DOC>
	<brief_summary>A 52-week follow up study to investigate the duration of maintenance of efficacy in patients with RA and achieved low disease activity in clinical trials of MRA and stopped the treatment</brief_summary>
	<brief_title>A Study of Duration of Maintained Efficacy in Rheumatoid Arthritis (RA) Patients Off Treatment With MRA(a Development Code of Tocilizumab, an Anti IL-6 Receptor Monoclonal Antibody.)</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Patients who achieved DAS28 of &lt; 3.2 at the last observation and at least one time point among the two previous assessment time points in a previous studies. Patients who receive DMARDs or immunosuppressants between the last observation in a previous studies and the first observation in this study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>